Kelly J Fitzgerald

US Patent:

20170087148, Mar 30, 2017

Filed:

Dec 9, 2016

Appl. No.:

15/374272

Inventors:

- New Haven CT, US
Kelly Fitzgerald - New Haven CT, US

International Classification:

A61K 31/4745
C07D 471/04

Abstract:

The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) and Toll-like receptor agonist (TLR) through a linker and a multifunctional connector group or molecule.

US Patent:

20160082112, Mar 24, 2016

Filed:

May 3, 2013

Appl. No.:

14/888779

Inventors:

- New Haven CT, US
Patrick McEnaney - New Haven CT, US
Kelly Fitzgerald - Upton MA, US

International Classification:

A61K 47/48
A61K 38/10
A61K 31/194
A61K 45/06

Abstract:

The present invention relates to compounds which function as antibody mimetic compounds. These compounds are bifunctional/multifunctional compounds which contain at least one cancer cell binding moiety which selectively binds to prostate specific membrane antigen (PSMA) and a FC receptor binding moiety which modulates an FC immune receptor, preferably a FcγRI receptor. Compounds according to the present invention bind selectively to cancer cells which upregulate PSMA and through that interaction, place the Fc receptor binding moiety of the compound in proximity to a Fc receptor, preferably a FcγRI receptor, which can modulate (preferably, upregulate) a humoral response in a patient to cancer cells. Through this biological action of the compounds according to the present invention, cancer cells, including metastatic cancer cells, especially prostate cancer cells can be immune regulated, resulting in the favorable therapy of cancer in a patient. Methods of using these compounds to treat cancer and/or reduce the likelihood of metastatis of cancer are additional aspects of the present invention.

US Patent:

20150110742, Apr 23, 2015

Filed:

May 1, 2013

Appl. No.:

14/397995

Inventors:

- NEW HAVEN CT, US
Kelly Fitzgerald - New Haven CT, US

Assignee:

Yale University - New Haven CT

International Classification:

C07D 471/04
A61K 45/06
A61K 31/53

US Classification:

424 857, 544198, 514245

Abstract:

The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) and Toll-like receptor agonist (TLR) through a linker and a multifunctional connector group or molecule.